ポスター：ADC Therapeutics社、抗体薬物複合体（ADC）のデザイン・製造・解析のための新たなワークフローシステム

10月 24, 2024

ADC Therapeutics社では、抗体のスクリーニングやエンジニアリングから、Drug-to-Antibody Ratio（DAR）やin vitro細胞毒性などのADC特有の分析まで、包括的なバイオ医薬品研究開発プラットフォームとしてGenedata Biologics^®を活用しています。本ポスターでは、ADC創薬の効率化とスループット向上について紹介しています。

ADC Therapeutics is proud to present this poster on Antibody Drug Conjugates (ADCs), a cutting-edge therapeutic strategy in oncology that utilizes the precision of monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells. The ADC development process is intricate, requiring optimal conjugation methods, linkers, and small-molecule toxophores. In this poster, ADC Therapeutics showcases their use of Genedata Biologics^® — a comprehensive biologics database that simplifies the entire ADC discovery process. This platform covers everything from antibody screening and engineering to expression, purification, drug conjugation, and ADC-specific analytics such as Drug-to-Antibody Ratio (DAR) and in vitro cytotoxicity. By integrating the registration and tracking of both complex biologics and small molecules, Genedata Biologics consolidates analytics and functional assay results into a unified system, significantly boosting the efficiency and throughput of ADC discovery.